Misplaced Pages

#553446

34-756: Boehringer (Böhringer) may refer to: Boehringer Ingelheim , a pharmaceutical company Boehringer Laboratories , an American medical technology company Boehringer Mannheim, a medical supplies company acquired by Roche Diagnostics Gebr. Boehringer ( de:Gebr. Boehringer ), original manufacturer of Unimog trucks Brian Boehringer (born 1969), former Major League Baseball pitcher Jorge Boehringer (born 1975), American musician Peter Boehringer (born 1969), German politician Robert Boehringer (1884–1974), German industrialist and poet Moritz Böhringer (born 1993), German American Football player See also [ edit ] Bohringer Topics referred to by

68-609: A "qui tam" (whistleblower) case with the U.S. government for $ 95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs. In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014,

102-419: A $ 650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug. In October 2023 Boehringer Ingelheim was ordered to pay a 10 million Euro fine for illegal price fixing that had gone on globally over

136-525: A checkpoint inhibitor antibody designed to treat solid tumors. In the same month Boehringer announced a partnership with Topas Therapeutics and their virus-based vectors. In mid-September the company exercised its option to acquire viral cancer therapy developer, ViraTherapeutics , for €210 million ($ 245 million). In March 2019, Boehringer announced it would acquire ICD Therapeutics. In July, subsidiary company Boehringer Ingelheim Pharmaceuticals, Inc. announced it had acquired Amal Therapeutics SA, boostings

170-735: A deal for Hanmi's Phase I cancer drug candidate, HM95573 , which targets the MAPK/ERK pathway ; Roche agreed to pay $ 80 million upfront, and the deal included $ 830 million in milestones. In December 2016 the Sanofi deal was reduced in scope, with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product, and agreeing to repay Sanofi $ 250 million of the $ 434 million upfront payment. On December 3, 2019, Rapt Therapeutics and Hanami Pharmaceutical announced collaboration to develop and commercialize FLX475 in Asia. FLX475

204-467: A developer of oncolytic virus therapies, dependent on the success of Phase I trials. In June 2016, the company announced it had struck an asset-swap deal with Sanofi , Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion / $ 12.4 billion). The deal could mean that Boehringer

238-499: A division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine . The company invested US$ 300,000,000 to upgrade the drug manufacturing plant, and limited production resumed in October 2012. However, on 3 October 2013, Ben Venue announced that it would be ceasing production by

272-834: A facility in Beijing. In July Hanmi said it intended to invest more heavily in developing candidate substances of promising new drugs at an early stage in new pharmaceutical and biotech related fields, including through a venture capital firm set up by Sung-ki and colleagues. In May 2016 the Korean regulatory authority approved olmutinib as a second-line treatment for certain kinds of non-small cell lung cancer . On September 28 Hanmi and Zentec Pharmaceuticals agreed that Zentec would market Hanmi's small molecule cancer drug candidate, HM95573 ; Zentec paid $ 80 million upfront, with $ 830 million in milestones, and royalties. On September 29, Hanmi and Roche 's cancer subsidiary Genentech announced

306-439: A new salt form of Amlodipine in 2004, and an anti-obesity drug using sibutramine mesilate in 2007. Hanmi and Crystal Genomics formed a strategic partnership in 2008. By around 2010, Hanmi's R&D had two areas of interest: developing longer-lasting peptide and protein therapeutics using its " Lapscovery " technology, and developing small molecule tyrosine-kinase inhibitors for cancer and autoimmune diseases. Its strategy

340-812: A newly established Quantum Lab of Boehringer Ingelheim. Boehringer Ingelheim is also a founding member of the Quantum Technology and Application Consortium (QUTAC). Prescription Medicines: Consumer Health Care (sold to Sanofi ): Animal Health: Also in companion animal portfolio: Purevax feline vaccines, Recombitek canine vaccine, Imrab rabies vaccine, NexGard (afoxolaner), NexGard Spectra (afoxolaner/milbemycin oxime), NexGard Combo ( esafoxolaner/eprinomectin/praziquantel ), Heartgard-30 Plus (ivermectin/pyrantel pamoate), Immiticide (melarsomine), Senvelgo (velagliflozin) Boehringer Ingelheim's product pipeline targets lung disease , cancer , and hepatitis C . In October 2012 Boehringer Ingelheim settled

374-409: A period of nearly fifteen years. Boehringer bears the largest share of an antitrust fine totaling € 13.4 million. Anyone affected by its anti-competitive behavior may claim damages, competition regulators stressed. As a private company, Boehringer Ingelheim (BI) is not required to disclose detailed financial information publicly; the owners have considered an IPO and ruled it out. In 2006,

SECTION 10

#1732775427554

408-407: A treatment being used in early trials against triple-negative breast cancer and lung cancer , for $ 1.5 billion. In June 2020, Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela) , a CDK4/6 inhibitor designed to prevent chemotherapy-induced myelosuppression . The agreement targets small cell lung cancer , will initially run for three years, and covers

442-507: Is a South Korean pharmaceutical company that is headquartered in Seoul . Hanmi was founded in 1973 by Lim Sung-ki, who was a pharmacist . It was originally named Lim, Sung-ki Pharmaceutical Co., but it was quickly changed to Hanmi Pharmaceutical. The company originally started selling Trimethoprim/sulfamethoxazole powder, and would expand to produce Cephalosporin antibiotics in 1985 and injectable Ceftriaxone antibiotics in 1987. By 1988

476-615: Is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993. In 2011, Ben Venue Laboratories in Bedford, Ohio ,

510-408: Is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers. In August 2020, chairman and founder of Hanmi Pharmaceutical Lim Sung-ki died of a chronic disease. He was 80. On May 15, 2023, Athenex, which was Hanmi's U.S. partner for its anticancer product, Oraxol, filed for Chapter 11 bankruptcy protection. On the evening of September 29, 2016, Hanmi announced

544-419: Is different from Wikidata All article disambiguation pages All disambiguation pages Boehringer Ingelheim The company supplied the most potent ingredient of Agent Orange . In 2004, the company acquired STEAG microParts GmbH. In December of the same year the company announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica. In June 2008,

578-433: Is now one of the animal healthcare global leaders. In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound ( BI 836909 , now AMG 420) for use in the treatment of multiple myeloma . As part of the asset swap, Boehringer and Merial sold a number of assets to Ceva Santé Animale - namely some animal health vaccines and pharmaceuticals from

612-523: The European Commission . On January 11, 2021, Boehringer Ingelheim announced a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing in

646-1248: The United States and Puerto Rico . In September 2021, the company announced it would acquire Abexxa Biologics, boosting its cancer immunotherapy research. In 2023, the World Intellectual Property Organization (WIPO) ’s Madrid Yearly Review ranked Boehringer's number of marks applications filled under the Madrid System as 4th in the world, with 118 trademarks applications submitted during 2023. Boehringer Ingelheim works in human pharmaceuticals , animal health , and biopharmaceuticals . The group consists of 145 affiliated companies with around 50,000 employees in 2017 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna , Kobe , and Milan (closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development. Boehringer Ingelheim

680-737: The Chairman of the Shareholders’ Committee Dr Heribert Johann retired and Christian Boehringer took over the position as chairperson of the board of directors . As of 2018 Christian Boehringer remains in this position. In 2015, then-CFO Hubertus von Baumbach took over the position of Chairman of the Board of Managing Directors, a CEO position, to replace Andreas Barner who had taken the position in 2009. Hanmi Pharmaceutical Hanmi Pharm Co., Ltd. ( Korean :  한미약품 주식회사 ; Hanja :  韓美藥品 株式會社 )

714-582: The Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities. In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $ 885 million, to Eli Lilly's Elanco Animal Health division. In April 2018, the company announced that it would launch an immuno-oncology partnership with OSE Immunotherapeutics worth up-to-$ 1.4 billion, focussing on developing OSE's late-preclinical-stage candidate OSE-172 ,

SECTION 20

#1732775427554

748-530: The Roche deal, causing its stock to rise; Hanmi was notified by Boehringer that evening that Boehringer was terminating their deal, and the company announced the termination on the morning of the 30th, causing its stock to crash. Hanmi's offices were raided by Korean regulatory authorities in mid-October based on evidence that insider knowledge of the Boehringer termination was passed to third parties, who shorted

782-858: The business' focus on cancer immunotherapy and vaccine treatments. In May 2020, the business announced it would acquire Northern Biologics Inc. which focuses on therapeutic antibodies targeting tumours. In June, the business announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $ 800 million. In July, the company announced it would acquire Global Stem cell Technology, boosting its animal health business. In December, Boehringer announced it would acquire Labor Dr. Merk & Kollegen, boosting its immuno-oncology therapy range including Vesicular Stomatitis Virus and cancer vaccines platforms and Swiss-based NBE Therapeutics, adding drug candidates including

816-471: The company acquired FX125L and the somatotaxin programme from Funxional Therapeutics for an undisclosed sum. In May 2015, the company acquired the investigational drug PXS4728A from Pharmaxis ’. In July, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $ 2.65 billion ($ 1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $ 125 million based on performance milestones. On

850-635: The company announced its intention to acquire Actimis Pharmaceuticals for $ 515 million, depending on the performance of Actimis' leading asthma compound AP768. In 2009, through its US subsidiary, Boehringer Ingelheim Vetmedica Inc., acquired a significant portion of the Fort Dodge Animal Health business from Pfizer . In 2010, BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares. In August 2012,

884-434: The company sold the commercialisation rights to BI 655066 ( Risankizumab ), to AbbVie for $ 595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for psoriasis , and in earlier testing for Crohn's disease , psoriatic arthritis and asthma . In September of the same year the company announced it would acquire ViraTherapeutics for €210 million ($ 230 million ),

918-600: The company was listed in the Korea Exchange . Hanmi started selling drugs in China in 1996. In 1994, the company began developing Cyclosporin . The company broke the ₩ 100,000,000,000 barrier in sales in 1997. The company began moving into the European market in 1998. The company still was developing new drugs, with Paclitaxel in 2000, Itraconazole tablets in 2001, 24-hour controlled-release Nifedipine tablets and

952-589: The end of 2013 due to being unable to "return to sustainable production." Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox . The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and

986-461: The field of autoimmune diseases ; Lilly paid $ 50 million upfront and the deal included up to $ 640 million in milestones and royalties greater than 10%. In November 2015 Hanmi signed three agreements: In April 2016 Hanmi announced that it had acquired land near Yantai in the Shandong province of China, where it would build a manufacturing plant and R&D facility; at that time it already had

1020-419: The same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713 , a third generation treatment for EGFR mutation-positive lung cancer . Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's. The company sold the rights to Faldaprevir , a HCV protease inhibitor to Trek Therapeutics. In July 2016,

1054-501: The same term [REDACTED] This disambiguation page lists articles associated with the title Boehringer . If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=Boehringer&oldid=1204742728 " Categories : Disambiguation pages Disambiguation pages with surname-holder lists German-language surnames Hidden categories: Short description

Boehringer - Misplaced Pages Continue

1088-469: The stock prior to the announcement on the 30th. In December three Hanmi employees were among 17 people indicted for insider trading; 25 people were fined, and 45 people were found to have made illegal trades that took around 3.3 billion won ($ 2.83 million) in profits based on the information. On September 30, 2016, Korean regulatory authorities issued a safety alert about olmutinib in which it described two cases of toxic epidermal necrolysis , one of which

1122-456: Was fatal, and a case of Stevens–Johnson syndrome ; Boeheringer announced the termination its deal with Hanmi the same day, citing that the decision came after a review of "all available clinical data" on the drug, and also referring to competing drugs. In April 2018 Hanmi was found to have violated two laws in Korea by not disclosing adverse effects of olmutinib sooner. In that month Zai said it

1156-649: Was to developmental incremental modifications of existing drugs, create new combination drugs , and to develop novel drugs. In August 2014 Hanmi exclusively licensed rights in China for poziotinib , a small molecule EGFR inhibitor , to the Chinese company Luye Pharma; in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum Pharmaceuticals. In March 2015 Hanmi and Lilly signed an exclusive license outside of Asia for Hanmi's small molecule Bruton's tyrosine kinase inhibitor in

#553446